8-K: RenovoRx Appoints Mark Voll as New CFO

RenovoRx, Inc. announced the appointment of Mark Voll, an experienced public company executive, as its new Chief Financial Officer, effective February 4, 2026, following the voluntary resignation of Ronald B. Kocak as Principal Accounting Officer.

Summary

• Ronald B. Kocak resigned from his position as Principal Accounting Officer, effective February 3, 2026, but will retain his role as Vice President and Controller with his current salary for 2026.
• Mark Voll was appointed Chief Financial Officer and Principal Financial and Accounting Officer, effective February 4, 2026.
• Mr. Voll brings over 30 years of experience in finance and accounting, having served as CFO for multiple public and private high-technology companies, including leading initial public offerings and managing company sales.
• He will serve as an independent contractor, compensated at $250 per hour, paid 50% in cash and 50% in vesting restricted stock units, and received an initial grant of 60,000 unvested restricted stock units.
• RenovoRx generated approximately $900,000 in revenue from RenovoCath sales for the first nine months of 2025, marking its transition from a solely clinical-stage company to a commercial one.
• The company is actively commercializing its FDA-cleared RenovoCath device and advancing its Phase III TIGeR-PaC clinical trial for IAG (intra-arterial gemcitabine).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the appointment of a highly experienced CFO with a strong track record in public markets and high-growth companies is a strategic move to support RenovoRx's commercial expansion and financial management, despite the previous officer's partial departure.

Positives

• The appointment of Mark Voll as CFO brings over 30 years of financial leadership experience, including a strong track record in guiding high-growth public companies through commercial buildout and strategic development.
• Mr. Voll's expertise in managing operations, leading IPOs, and managing company sales is expected to strengthen RenovoRx's C-Suite leadership and support its commercial growth.
• RenovoRx has successfully transitioned to a commercial stage, evidenced by approximately $900,000 in RenovoCath sales for the first nine months of 2025.
• The company has received initial and repeat commercial purchase orders for RenovoCath, including from esteemed, high-volume National Cancer Institute-designated centers.
• The IAG product candidate has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

Negatives

• Ronald B. Kocak, the previous Principal Accounting Officer, resigned from that specific role, although he remains with the company as Vice President and Controller.
• Mark Voll is engaged as an independent contractor, which may imply a less permanent or full-time commitment compared to a traditional employee CFO role.
• The compensation structure for Mr. Voll, with 50% in restricted stock units, is subject to the approval of the Company's Compensation Committee, which could introduce some uncertainty or potential for dilution.

Risks

• The exploration of commercial opportunities for the TAMP technology may not lead to viable, revenue-generating operations.
• Circumstances could adversely impact the company's ability to efficiently utilize cash resources or raise additional funding.
• Uncertainty exists regarding the timing, progress, and potential results of preclinical studies, clinical trials, and research programs.
• Interim results from clinical trials may not be predictive of final outcomes, and trials may not demonstrate sufficient safety and efficacy to support regulatory approval of product candidates.
• Regulatory authorities may disagree with the company's interpretation of data, research, and clinical development plans and timelines.
• The company's ability to successfully manufacture and supply product candidates for clinical trials and for commercial use, if approved, is a risk.
• The ability to retain key personnel and to identify, hire, and retain additional qualified personnel is crucial for the company's success.
• The scope of protection the company is able to establish and maintain for intellectual property rights, including its therapy platform and product candidates, is a significant risk.
• Dependence on third-party suppliers and manufacturers and their ability to perform adequately poses a risk.
• Uncertainty surrounds the pricing, coverage, and reimbursement of product candidates, if approved.
• Developments relating to competitors and the industry, including competing product candidates and therapies, could impact the company's market position.

Future Outlook

RenovoRx aims to capitalize on its evolving model, transitioning from a clinical-stage to a commercial company. The company plans to continue the commercialization of its FDA-cleared RenovoCath drug-delivery device and advance its Phase III TIGeR-PaC clinical trial for IAG. It will actively explore further revenue-generating activities, potentially with a medical device commercial partner, to meet anticipated demand. The new CFO is expected to play a forward-facing role in stockholder communications and leverage his expertise in budgeting, strategic planning, and finance.

Management Comments

• "We are thrilled to welcome Mark to the RenovoRx leadership team during this important chapter of our company’s history. During 2025, we moved from being solely a clinical stage company to a commercial one as well. Mark is therefore joining us at a perfect time as we look to capitalize on our evolving model. His financial and operational leadership experience in both public markets and high-growth organizations will play a critical role as RenovoRx continues its drive towards sustained commercial execution." Shaun Bagai, CEO of RenovoRx.
• "I’ve worked with many emerging growth companies in my career, and I believe that RenovoRx right now is very well positioned at the intersection of innovation and patient impact, with a differentiated therapy platform and a clear strategic vision for transforming the lives of cancer patients. I have spent my career helping high-growth companies scale, and I am excited to bring that experience to RenovoRx. The team has built a strong foundation and has positive momentum, and I look forward to collaborating with leadership and the entire organization to further accelerate RenovoRx’s success." Mark Voll, Chief Financial Officer.

Industry Context

StockSavvy.ai notes that the appointment of a seasoned CFO with a strong background in scaling high-growth technology companies and managing IPOs is a strategic move for RenovoRx as it transitions from a clinical-stage to a commercial entity. This aligns with a broader industry trend where life sciences companies, upon achieving FDA clearance and initial commercial success, seek to bolster their financial leadership to navigate market expansion, potential capital raises, and investor relations, especially in competitive oncology and medical device sectors.

Comparison to Industry Standards

• Mark Voll's experience leading IPOs and managing company sales for Techwell, Inc., Montage Technology, and Aquantia Corporation demonstrates a track record comparable to financial leaders at other successful high-growth technology and life sciences firms.
• The reported $900,000 in RenovoCath sales for the first nine months of 2025 provides an initial commercial benchmark for a newly commercialized medical device, which can be compared against similar early-stage product launches in the medical device industry, though specific comparable company data is not provided in the filing.
• The compensation structure for a consulting CFO, including a mix of cash and restricted stock units, is a common practice for emerging growth companies seeking to attract experienced talent while managing cash burn.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for enhanced financial leadership and strategic direction, which could lead to improved commercial execution and long-term value. The equity component of the CFO's compensation aligns his interests with shareholders.
• Employees: The finance team will continue to include Ronald B. Kocak and Lilly Huang, suggesting continuity and support for the new CFO, potentially fostering a stable work environment.
• Customers: Continued commercialization of RenovoCath and advancement of clinical trials could lead to more innovative solutions and improved patient outcomes in oncology.

Next Steps

• Continue commercialization of the RenovoCath drug-delivery device.
• Advance the Phase III TIGeR-PaC clinical trial for IAG.
• Actively explore further revenue-generating activities, potentially with a medical device commercial partner.
• Mark Voll to serve in a forward-facing role in stockholder communications and leverage his expertise in budgeting, strategic planning, and finance.
• Mark Voll to oversee Finance, Accounting, Tax, Controllership, Information Technology, Acquisitions & Divestitures, and Insider Trading Compliance functions.

Key Dates

Recommendation

The appointment of a highly experienced CFO is a positive step for RenovoRx as it navigates commercialization and clinical trials. However, the company remains in early stages of commercial growth with a novel drug-device combination still under investigation. While the new leadership is a strong signal, the inherent risks associated with clinical trials and market adoption for a life sciences company suggest a 'hold' position until further clarity on commercial traction and clinical trial outcomes emerges.

Keywords

RenovoRx, RNXT, CFO Appointment, Chief Financial Officer, Mark Voll, Executive Change, Corporate Governance, Financial Leadership, RenovoCath, TAMP therapy, Oncology, Drug Delivery Device, Clinical Trial, TIGeR-PaC, Pancreatic Cancer, Bile Duct Cancer, Orphan Drug Designation, Commercialization, Life Sciences, Nasdaq